Palleiko Benjamin L 4
4 · KalVista Pharmaceuticals, Inc. · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
KalVista (KALV) CEO Benjamin Palleiko Sells Shares
What Happened Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals (KALV), had 15,625 restricted stock units (RSUs) convert to common shares on 2026-03-06. Following that vesting/settlement, he sold 6,693 shares in an open-market "sell-to-cover" transaction on 2026-03-09 for approximately $107,633 (reported weighted-average price shown as $16.08). The RSU conversion did not require cash payment by the insider.
Key Details
- Primary actions: RSU settlement (conversion/exercise) of 15,625 shares on 2026-03-06; open-market sale of 6,693 shares on 2026-03-09.
- Sale proceeds: $107,633 (reported price in table $16.08; filing notes weighted-average prices in the range $16.08–$16.4102).
- Reason for sale: sell-to-cover to satisfy tax withholding obligations in connection with RSU vesting (footnote F2); not a discretionary investment sale by the CEO.
- RSU terms: each RSU converts to one share for no consideration (F1); vesting schedule is 1/16th of total RSUs each quarterly anniversary beginning June 6, 2024 (F4).
- Shares owned after the transactions: not specified in the Form 4 filing.
Context
- This sequence is a routine RSU vesting and tax-withholding sale (common for employees/executives); the insider converted RSUs into shares and sold a portion immediately to cover taxes. The filing does not indicate a separate market-timed investment decision.
Insider Transaction Report
Form 4
Palleiko Benjamin L
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-06+15,625→ 458,508 total - Sale
Common Stock
[F2][F3]2026-03-09$16.08/sh−6,693$107,633→ 451,815 total - Exercise/Conversion
Restricted Stock Unit
[F1][F4]2026-03-06−15,625→ 125,001 total→ Common Stock (15,625 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.08 to $16.4102 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on June 6, 2024, subject to continued service through each vesting date.
Signature
/s/ Benjamin L. Palleiko|2026-03-10